SUPERIOR COURT OF NEW JERSEY
APPELLATE DIVISION
A-4238-97T2
DOLORES GURRIERI,
Plaintiff-Appellant,
v.
WILLIAM ZINSSER & CO., INC.,
a Corp. or Business Organization,
Defendant-Respondent.
___________________________________
Argued: March 24, 1999 - Decided: May 4, 1999
Before Judges King, Wallace and Newman.
On appeal from the Superior Court of New
Jersey, Law Division, Morris County.
Richard B. Livingston argued the cause for
appellant.
Daniel K. Newman argued the cause for
respondent.
The opinion of the court was delivered by
KING, P.J.A.D.
WARNING: FLAMMABLE (SEE OTHER CAUTIONS ON BACK
PANEL)
On the back of the can appeared:
CAUTION: FLAMMABLE. Contains alcohol. Keep away from heat, sparks, and open flame. Use with adequate ventilation. Avoid prolonged breathing of vapor or contact with skin. Do not take internally. Close can after using.
Our primary concern on the first appeal, as on this appeal,
was the validity of the federal-preemption defense asserted by
Zinsser, which claimed compliance with the FHSA. Both plaintiff
and defendant agree that methyl alcohol was the hazardous substance
contained in Zinsser's product and within the scope of the FHSA.See footnote 1
We concluded at that time, as we do now on this record, that
Zinsser's product contained less than 4" methyl alcohol. The
"stain-killer" contains about 2" methyl alcohol and did not need to
carry the special poison label (skull and crossbones) pursuant to
16 C.F.R. § 1500.14(b)(4) required of products with 4" or more
methyl alcohol. At the time of the first appeal, the record was
unclear as to whether the FHSA required any other warning label on
the product, or perhaps no label at all. Intertwined with this
uncertainty were the questions of federal regulatory preemption and
a duty to warn in a state common law or statutory product liability
context. See Restatement (Third) of Torts: Prods. Liab. § 2(c) at
14 (inadequate instructions or warning) and § 4 at 122, comment e
(regulatory compliance) (1998); N.J.S.A. 2A:58C-4 (adequate product
warning or instruction); William A. Dreier, The Restatement (Third)
of Torts: Products Liability and New Jersey Law .... Not Quite
Perfect Together,
50 Rut. L. Rev. 2059, 2089 (1998).
On the hearing after remand, Zinsser contended no federal
standard applied where the product contained less than 4" methyl
alcohol. Zinsser also claimed that the FHSA had completely
preempted all warning label requirements and the State of New
Jersey could apply no requirements of any kind, under common law or
otherwise. The plaintiff argued that for products with under 4" methyl alcohol, as here, the state common law or product liability
law filled the vacuum left in the absence of a federal standard.
Plaintiff relied on an expert who reported that the described label
on the "stain-killer" was inadequate, creating a jury question on
the issue of liability. Defendant presented no expert on warning
or labeling to contradict plaintiff's expert; defendant rested
solely on the regulatory-preemption defense. We now conclude that
15 U.S.C.A.
§1261(p) sets the warning-label standard for this
concededly "household product" with less than 4" methyl alcohol,
available commercially for both retail and industrial consumers.
We also conclude that Zinsser's "stain-killer" meets this § 1261(p)
federal statutory standard and affirm the grant of summary
judgment.
(1) which states conspicuously (A) the
name and place of business of the
manufacturer, packer, distributor or seller;
(B) the common or usual name or the chemical
name (if there be no common or usual name) of
the hazardous substance or of each component
which contributes substantially to its hazard,
unless the Commission by regulation permits or
requires the use of a recognized generic name;
(C) the signal word "DANGER" on substances
which are extremely flammable, corrosive, or
highly toxic; (D) the signal word "WARNING" or
"CAUTION" on all other hazardous substances;
(E) an affirmative statement of the principal
hazard or hazards, such as "Flammable",
"Combustible", "Vapor Harmful", "Causes
Burns", "Absorbed Through Skin", or similar
wording descriptive of the hazard; (F)
precautionary measures describing the action
to be followed or avoided, except when
modified by regulation of the Commission
pursuant to section 1262 of this title ....
The FHSA was enacted in 1960.
The purpose of the FHSA was to "provide nationally uniform
requirements for adequate cautionary labeling of packages on
hazardous substances which are sold in interstate commerce and are
intended or suitable for household use." H.R Rep. No. 86-1861, at
1 (1960), reprinted in 1
960 U.S.C.C.A.N. 2833. The FHSA, as first
enacted in 1960, did not contain a preemption provision. However,
the FHSA was amended in 1966 and a strong preemption provision was
added which states:
[I]f a hazardous substance or its packaging is
subject to a cautionary labeling requirement
under section 2(p) or 3(b) [subsec. (p) of
this section or section 1262(b) of this title]
designed to protect against a risk of illness
or injury associated with the substance, no
State or political subdivision of a State may
establish or continue in effect a cautionary
labeling requirement applicable to such
substance or packaging and designed to protect
against the same risk of illness or injury
unless such cautionary labeling requirement is
identical to the labeling requirement under
section 2(p) or 3(b) [subsec. (p) of this
section or section 1262(b) of this title].
[15 U.S.C.A. Sec. 1261, note (b)(1)(A) (1998)
(emphasis added).]
Additionally,
15 U.S.C.A.
§1262(b), entitled "Reasonable
variations or additional label requirements," provides that if the
Consumer Product Safety Commission (Commission) finds that the
requirements of § 1261(p) are not adequate for the protection of
public health and safety in light of a special hazard presented by
a hazardous substance, the Commission may establish by regulation
reasonable variations or additional label requirements. Any
hazardous substance intended as suitable for household use or by
children which fails to bear the label in accordance with the
regulations made by the Commission is deemed a "misbranded
hazardous substance."
15 U.S.C.A.
§1262(b) (1998). As noted,
defendant Zinsser's "stain-killer" concededly was a product
suitable for household use.
Pursuant to the mandate of
15 U.S.C.A.
§1262(b), the
Commission promulgated regulations with regard to specific,
especially hazardous substances. 16 C.F.R. § 1500.14, entitled
"Product requiring special labeling under § 3(b) of the Act"
states, in pertinent part:
(b) The Commission finds that the following
substances present special hazards and that,
for these substances, the labeling required by
section 2(p)(1) [
15 U.S.C.A.
§1261(p)(1)] of
the act is not adequate for the protection of
the public health. Under section 3(b) of the
act, the following specific label statements
are deemed necessary to supplement the
labeling required by section 2(p)(1) of the
act:
(4) Methyl alcohol (methanol). Because
death and blindness can result from the
ingestion of methyl alcohol, the label for
this substance and for mixtures containing 4
percent or more by weight of this substance
shall include the signal word "danger," the
additional word "poison," and the skull and
crossbones symbol. The statement of hazard
shall include "Vapor harmful" and "May be
fatal or cause blindness if swallowed." The
label shall also bear the statement "Cannot be
made nonpoisonous."
[Emphasis added.]
This special label was not required for Zinsser's "stain-killer,"
which contained only 2" methyl alcohol. Thus we resort to the
applicable alternative standards in § 1261(p)(1) for hazardous
substances for use in the household.
The law of federal preemption to a large extent defies useful
generalization. The cases are very specific to the regulated
subject. See William A. Dreier, Hannah G. Goldman & Eric D. Katz,
New Jersey Products Liability & Toxic Torts Law § 6.3-5 at 88
(1999). Two United States Supreme Court cases address the issue of
federal preemption inadequate labeling and failure-to-warn claims
brought under state law. First, in Cipollone v. Liggett Group,
Inc.,
505 U.S. 504,
112 S.Ct. 2608,
120 L.Ed.2d 407 (1992), the
Supreme Court considered whether preemption provisions contained in
§§ 4 and 5 of the Federal Cigarette Labeling and Advertising Act of
1965 (1965 Act) and the Public Health Cigarette Smoking Act of
1969 (1969 Act),
15 U.S.C.A.
§§1331 to 1340, preempted common-law
claims against cigarette manufacturers. Section 4 of the 1965 Act
made it unlawful to sell or distribute any cigarettes of the United
States unless the package had a label stating: "Caution: Cigarette
Smoking May Be Hazardous To Your Health." Cipollone v. Liggett
Group, Inc., 505 U.S. at 514, 112 S.Ct. at 2616, 120 L.Ed.
2d at
421. Section 5 of the 1965 Act, captioned "Preemption," provided
in part:
(a) No statement relating to smoking and
health, other than the statement required by
section 4 of this Act, shall be required on
any cigarette package.
(b) No statement relating to smoking and
health shall be required in the advertising of
any cigarettes the packages of which are
labeled in conformity with the provisions of
this Act.
[Ibid.]
Later, Congress passed the 1969 act and replaced § 5(b) of the 1965
act with this provision:
[5](b) No requirement or prohibition
based on smoking and health shall be imposed
under state law with respect to the
advertising or promotion of any cigarettes the
packages of which are labeled in conformity
with the provisions of this Act.
[Cipollone v. Liggett Group, Inc., 505 U.S. at
515; 112 S.Ct. at 2617, 120 L.Ed.
2d at 422.]
Regarding § 5(b) of the 1969 Act, the Supreme Court stated:
The phrase "[n]o requirement or prohibition"
sweeps broadly and suggests no distinction
between positive enactments and common-law; to
the contrary, those words easily encompass
obligations that take the form of common law
rules. As we noted in another context,
"[state] regulation can be as effectively
exerted through an award of damages as through
some form of preventive relief. The
obligation to pay compensation can be, indeed
is designed to be, a potent method of
governing conduct and controlling policy."
[Cipollone v. Liggett Group, Inc., 505 U.S. at
521, 112 S.Ct. at 2620, 120 L.Ed. at 426
(quoting San Diego Building Trades Council v.
Garmon,
359 U.S. 236, 247,
79 S.Ct. 773, 780,
3 L.Ed.2d 775 (1959)).]
The Court concluded that the failure-to-warn claims were preempted
to the extent that the advertising or promotions should have
included additional, more clearly-stated warnings. Cipollone v.
Liggett Group, Inc., 505 U.S. at 524, 112 S.Ct. at 1261, 120
L.Ed.
2d at 428. However, the Supreme Court also held that claims
based solely on negligent testing or research, by contrast, were
not preempted. Cipollone v. Liggett Group, Inc., 505 U.S. at 524-25, 112 S.Ct. at 2621-22, 120 L.Ed.
2d at 428. Thus, the Supreme
Court found specific Congressional intent to preempt common-law
claims based on alleged inadequate labeling of cigarette package
labels.
In the second pertinent United States Supreme Court case,
Medtronic, Inc. v. Lohr,
518 U.S. 470, 474,
116 S.Ct. 2240, 2245,
135 L.Ed.2d 700, 709 (1996), the Court considered whether the
Medical Device Amendments of 1976 (MDA) preempted a state common-law negligence claim against the manufacturer of an allegedly
defective medical device. The preemption provision of the MDA
provides:
(a) General rule
Except as provided in subsection (b) of
this section, no State or political
subdivision of a State may establish or
continue in effect with respect to a device
intended for human use any requirement....
(1) which is different from, or in
addition to, any requirement applicable under
this chapter to the device, and
(2) which relates to the safety or
effectiveness of the device or to any other
matter included in a requirement applicable to
the device under this chapter.
[
21 U.S.C.A.
§360k(a)(1)(2).]
The Court stated that Congress' statutory intent is discerned from
the language of the preemption statute and the "statutory
framework" surrounding it. Medtronic, Inc. v. Lohr, 518 U.S. at
486, 116 S.Ct. at 2250-51, 135 L.Ed.
2d at 716 (citing Gide v.
National Solid Wastes Management Assn,
505 U.S. 88, 111,
112 S. Ct. 2374,
120 L.Ed.2d 73 (1992) (Kennedy, Jr., concurring in part and
concurring in judgment)). The Court also stated the relevancy of
the structure and purpose of the statute as a whole as revealed not
only in the text but through the reviewing court's reasoned
understanding of the way in which Congress intended the statute and
its surrounding regulatory scheme to affect business, consumers,
and the law. Medtronic, Inc. v. Lohr, 518 U.S. at 486, 116 S.Ct.
at 2251, 135 L.Ed.
2d at 716. Regarding this "statute as a whole"
analysis, the Supreme Court explained that pursuant to the
regulatory scheme established by the MDA, a large portion of the
medical devices do not receive anything more than a cursory or
superficial review before marketing. Medtronic, Inc. v. Lohr, 518
U.S. at 477-78, 116 S.Ct. at 2247, 135 L.Ed.
2d at 711-12.
In light of this, the Supreme Court held the MDA did not
preempt plaintiff's failure-to-warn claims and in doing so stated
the following:
[T]he predicate for the failure to warn claim
is the general duty to inform users and
purchasers of potentially dangerous items of
the risks involved in their use. These
general obligations are no more a threat to
federal requirements than would be a state-law
duty to comply with local fire prevention
regulations and zoning codes, or to use due
care in the training and supervision of a
workforce. These state requirements therefore
escape pre-emption, not because the source of
the duty is judge-made common-law rule, but
rather because their generality leaves them
outside the category of requirements that
§360k envisioned to be "with respect to"
specific devices such as pacemakers.
[Medtronic, Inc. v. Lohr, 518 U.S. at 501-02,
116 S.Ct. at 2258, 135 L.Ed.
2d at 725-26.]
Our State's labeling cases are analytically helpful. In
Macrie v. SDS Biotech Corp.,
267 N.J. Super. 34, 37 (App. Div.),
certif. denied,
134 N.J. 65 (1993), plaintiffs were employees of a
produce broker who were exposed to Bravo 500, a fungicide
manufactured by defendant SDS Biotech Corp., and used by farmers on
their crops in the field. The farmer who initially applied the
fungicide did not properly follow the application directions
supplied by the defendant manufacturer. When the plaintiffs'
employer purchased the crops with the fungicide from the farmer,
the fungicide particles became airborne, permeated plaintiffs'
employer's building, and caused serious injury to plaintiffs' lungs
and skin. We addressed the issue of whether plaintiffs' negligence
claims were preempted and controlled by the Federal Insecticide,
Fungicide and Rodenticide Act (FIFRA),
7 U.S.C.A.
§§136 to 136y.
Id. at 44-45. We stated that FIFRA is a "comprehensive regulatory
statute" regulating the use, sale, and labeling of pesticides
produced and sold in both intrastate and interstate commerce. Id.
at 45. We observed that FIFRA deals with preemption in the
following terms:
(a) In general
A State may regulate the sale or use of
any federally registered pesticide or device
in the State, but only if and to the extent
the regulation does not permit any sale or use
prohibited by this subchapter.
(b) Uniformity
Such State shall not impose or continue
in effect any requirements for labeling or
packaging in addition to or different from
those required under this subchapter.
[Id. at 45 (quoting
7 U.S.C.A.
§136v(a),
(b)).]
In interpreting this language in FIFRA, we referred to the then-recent United States Supreme Court decision, Cipollone v. Liggett
Group, Inc., 505 U.S. at 504, 112 S.Ct. at 2608, 120 L.Ed.
2d at
407, regarding federal preemption. We stated that in Cipollone the
Supreme Court held that the statutory language of the Public Health
Cigarette Smoking Act of 1969, which was similar to § 136v(b) of
FIFRA, preempted failure-to-warn damage actions against cigarette
manufacturers based on allegedly inadequate or misleading labeling.
Macrie v. SDS Biotech Corp., 267 N.J. Super. at 45-46. We said,
however, that both before and after Cipollone, federal courts have
been divided over whether FIFRA preempts state law failure-to-warn
damage actions based on inadequate labeling. Id. at 46. We relied
extensively on New York State Pesticide Coalition v. Jorling, 874
F.2d. 115 (2d Cir. 1989), which explained that warnings which
pesticide manufacturers and applicators are required to give to
persons other than users who are not direct purchasers in order to
protect the safety of those persons are not preempted because they
are not "labeling" within the meaning of § 136(p)(2) of FIFRA.
Macrie v. SDS Biotech Corp., 267 N.J. Super. at 47. In reliance on
this "labeling" versus "warning" distinction, we found there was no
federal preemption of state law claims and held that state law may
require a pesticide manufacturer to take reasonable steps to assure
that persons who handle produce bought directly from farmers who
used defendant's fungicide will be warned of its dangers, at least
by receiving defendant's brochures prescribed by the E.P.A. Id. at
48-49.
In Lewis v. American Cyanamid Co.,
294 N.J. Super. 53, 56-57
(App. Div. 1996), aff'd as modified,
155 N.J. 544 (1997)See footnote 2, another
case involving FIFRA, plaintiff Lewis was burned when the flame
from the pilot light of a gas oven or spark from his refrigerator
motor ignited gaseous hydrocarbon propellants that were released
into the air by plaintiff's use of defendant's aerosol insecticide.
We held that plaintiff's claims based on inadequate labeling were
preempted by FIFRA. We based our decision on the seminal United
States Supreme Court cases, Cipollone v. Liggett Group, Inc., and
Medtronic, Inc. v. Lohr. Id. at 64. We recognized that the two
cases reached different results because the Court concluded that
the legislative intent reflected in the legislation at issue in
Cipollone was different from that reflected in the legislation
subject of Medtronic. Ibid. We also stated that unlike the
statutes in Cipollone, the Medtronic statute and its implementing
regulations did not prescribe any specific language for labeling
and its preemption provision did not contain any express statement
of an intent to preempt state labeling requirements. Id. at 65.
We stated that Medtronic was also different from Cipollone because
the regulatory scheme for the life-dependent medical devices (e.g.,
pacemakers) in Medtronic received only a superficial review before
marketing. Ibid. Against this regulatory background, we concluded
this a substantial reason the Supreme Court rejected the
manufacturer's preemption defense in Medtronic. Id. at 66. We
found that the preemption provisions of FIFRA were more like the
provisions involved in Cipollone than the provisions in Medtronic.
Ibid. We also found that FIFRA, similar to the statutes at issue
in Cipollone, left unconstrained all state common-law actions for
defective products except those based on inadequate labels. Ibid.
As a result, we held that plaintiff's failure-to-warn claims were
federally preempted. Id. at 67. See also Hawkins v. Leslie's
Poolmart,
965 F.Supp. 566 (D.N.J. 1997) (plaintiff's claims based
on inadequate labeling and packaging of container of chlorine
tablets were preempted by FIFRA).
In a case very much like the matter before us, Canty v. Ever-Last Supply, Co.,
296 N.J. Super. 68, 73 (Law Div. 1996), plaintiff
was killed and his son was injured when vapors from a lacquer floor
sealant, "Lacquer Seal," which they had applied to a hardwood
floor, suddenly burst into flames. The primary issue on the
summary judgment motion by defendants was whether plaintiff's
defective warning claims were preempted by the FHSA,
15 U.S.C.A.
§§1261 to 1278. Plaintiff's expert submitted a report claiming that
the warnings on the Lacquer Seal were "poorly organized" and that
the label did not provide adequate information about the flammable
nature of Lacquer Seal vapors or the kinds of precautions that
users should take concerning how to properly ventilate rooms before
using the product. Id. at 75. In contrast, the expert for
defendant stated the label in question contained conspicuous
warnings, detailed instructions, and complied with applicable
federal law. Regarding federal preemption of plaintiff's state law
claims, Judge Julio M. Fuentes, relying on Cipollone v. Liggett
Group, Inc., stated that there must be a clear showing of
Congressional intent to supersede state authority because there is
a strong presumption against preemption. Id. at 80-81. Judge
Fuentes recited the preemption provision added to the FHSA through
the amendment in 1966:
[I]f a hazardous substance or its packaging is
subject to a cautionary labeling requirement
under [the FHSA] designed to protect against a
risk of illness or injury associated with the
substance, no State or political subdivision
of a State may establish or continue in effect
a cautionary labeling requirement applicable
to such substance or packaging and designed to
protect against the same risk of illness or
injury unless such cautionary labeling
requirement is identical to the labeling
requirement under [the FHSA].
[Id. at 81-82 (quoting
15 U.S.C.A.
§1261,
Historical Note, Effect upon Federal and State
Law).]
Applying this section, Judge Fuentes found that the history and
purpose of this preemption provision made clear that Congress
intended to preempt all state laws which establish cautionary
labeling requirements different from those established by the FHSA.
Id. at 82. In reliance on Cipollone v. Liggett Group, Inc., Judge
Fuentes held that where a plaintiff's claim seeks to hold a
manufacturer responsible for failing to provide warning labels
which are not identical to but stronger than those required under
the FHSA, the claim is preempted and fails. Id. at 84. However,
where a plaintiff does not seek more elaborate labeling
requirements, but rather asserts an alleged failure to comply with
the FHSA, such a claim would not impose "a labeling requirement"
and would not be preempted. Ibid. As a result, Judge Fuentes,
based on his perception of the "weight of authority," concluded
that a failure-to-warn claim could be brought but only for failure
to comply with the FHSA's labeling provisions. Id. at 85.
In determining whether defendant's Lacquer Seal product
complied with the FHSA, Judge Fuentes recognized that the labeling
requirements were contained within the statute and its regulations
which provided a "loose" framework of instructions applicable to
products that are "hazardous substances" within the meaning of the
FHSA. Id. at 86. Judge Fuentes also stated that unlike other
types of labeling statutes the FHSA and its regulations do not
dictate specific warning language but rather provide that a
hazardous substance will be considered "misbranded" and
noncompliant if the label fails to include certain basic
information about the product, its contents, and its proper use.
Ibid. In this discussion the judge referred to both
15 U.S.C.A.
§1261(p)(1) and 16 C.F.R. § 1500.3(b)(14). He also found that the
Consumer Product Safety Commission (Commission) was the agency
which oversees enforcement of the FHSA and it does not require
formal approval of a label before a hazardous product may be
introduced into commerce. Canty v. Ever-Last-Supply Co., 296 N.J.
Super. at 91. However, as Judge Fuentes noted, the Commission
provides sample warnings for certain products. Although there was
no specific sample provided for lacquer, the sample warning for
"contact adhesives" appeared applicable because these products,
like lacquers, have a flash-fire propensity. Ibid. In using and
comparing the sample warnings which the Commission formulated for
"contact adhesives," he found the label on defendant's product
adequately complied with the FHSA requirements. Id. at 92.
Also of interest is Busch v. Graphic Color Corp.,
169 Ill.2d 325,
662 N.E.2d 397, cert. denied, Busch v. AMREP, Inc., 519 U.S.
810,
117 S.Ct. 55,
136 L.Ed.2d 18 (1996), where plaintiff's
decedent died as a result of inhalation of methylene chloride after
using "Misty Paint Stripper" manufactured by defendant AMREP. In
applying Cipollone and its progeny, the Illinois Supreme Court
found that the FHSA's preemption provision precludes common-law
tort claims which seek to impose cautionary labeling requirements
different from the FHSA and which were designed to protect against
the same risk of illness or injury as those imposed by the FHSA.
Id. at 406. The Illinois court also stated that despite the fact
the provisions of
15 U.S.C.A.
§1261(p) are couched in general
terms encompassing every type of hazardous substance, they are
nonetheless requirements for the cautionary labeling of hazardous
substances which included defendant's Misty Paint Stripper. Id. at
407. The court also noted that Congress made this clear as it
referred to the provisions of § 1261(p) as cautionary labeling
"requirements" in the language of the FHSA's preemption provisions.
Ibid. (citing
15 U.S.C.A.
§1261 note (b)(1)(A) (1988)). Further,
the court found that the Consumer Product Safety Commission, the
federal agency responsible for administering the FHSA, offered a
detailed exemplar label for paint stripper products containing
methylene chloride which the Commission concluded conformed to the
labeling requirements set forth in § 1261(p) of the FHSA. Ibid.
The court also found that the Commission had concluded that its
detailed labeling example satisfied the cautionary labeling
requirement of § 1261(p) of the FHSA. Ibid. In finding that the
label on defendant's product was virtually identical to the
exemplar label provided by the Commission, the court stated that
labeling requirements which plaintiff sought to impose on defendant
were not "identical" to the labeling required under
15 U.S.C.A.
§1261(p)(1). This resulted in preemption of plaintiff's failure-to-warn claims. Busch v. Graphic Color Corp., 169 Ill.
2d at 345, 662
N.E.
2d at 407-08. See also Moss v. Parks Corp.,
985 F.2d 736 (4th
Cir.), cert. denied,
509 U.S. 906,
113 S.Ct. 2999,
125 L.Ed.2d 693
(1993)(common-law tort action based upon failure to warn may only
be brought for non-compliance with existing federal labeling
requirements; if plaintiff requires a more elaborate or different
label than required by the FHSA and its regulations, the claim is
preempted); Salazar v. Whink Products Co.,
881 P.2d 431 (1994),
cert. denied,
514 U.S. 1004,
115 S.Ct. 1315,
131 L.Ed.2d 196
(1995)(to the extent that plaintiff sought additional, different or
more clearly-stated warnings, claim was expressly preempted by the
FHSA); see also Kirstein v. W.M. Barr & Company, Inc.,
983 F. Supp. 753, 760-61 (N.D. Ill. 1997) (same as to adhesive remover),
affirmed,
159 F.3d 1065 (7th Cir. 1998); Comeaux v. National Tea
Co.,
81 F.3d 42, (5th Cir. 1996) (warning on lighter fluid for
naptha complied with FHSA and state claim for defective warning
preempted).
In the present case, the 1966 preemption amendment to the FHSA
interpreted in light of the intent of Congress to provide
"nationally uniform requirements for adequate cautionary labeling,"
as expressed with the passage of the FHSA in 1960, demonstrates
Congress' specific design to preempt state failure-to-warn labeling
claims. H.R. Rep. No. 86-1861, at 1 (1960), reprinted in 1
960 U.S.C.C.A.N. 2833. This conclusion is also supported by the
Supreme Court's reasoning in Cipollone which is doctrinally similar
to the present case. Both situations demonstrate strong
Congressional language supporting a policy of federal labeling
preemption. Similar to the circumstances in Lewis, Canty, and
Busch, the plaintiff in the present case proposes additional label
warnings not "identical" to the labeling requirements under the
federal act. Specifically, plaintiff urges through his expert that
additional warnings not required by the federal law, were necessary
on products containing less than 4" of methyl alcohol. As in
Lewis, Canty, and Busch, to the extent that the plaintiff proposes
additional, different, or more clearly-stated warnings, these
claims are preempted by the FHSA.
In the present case, both
15 U.S.C.A.
§1261(p) and the
regulations provided in 16 C.F.R. § 1500.14, promulgated pursuant
to
15 U.S.C.A.
§1262(b), address the labeling of hazardous or
dangerous substances. As stated previously, 16 C.F.R. § 1500.14
entitled "Product requiring special labeling under § 3(b) of the
Act" specifically addresses additional labeling (e.g., "danger,"
"poison," the "skull and crossbones symbol," "Vapor harmful," and
"May be fatal or cause blindness if swallowed") required when 4" or
more of methyl alcohol by weight is contained in a product. A
finding that specific local warnings pursuant to state law must
apply to products containing less than 4" of methyl alcohol would
create a system of possibly fifty or more different labeling
requirements throughout the country, contrary to Congress' obvious
intent in passing the FHSA to "provide nationally uniform
requirements for adequate cautionary labeling." House Comm. On
Interstate and Foreign Commerce, Federal Hazardous Substances
Labeling Act, H.R. Rep. No. 86-1861 at 1 (1960), reprinted in 1
960 U.S.C.C.A.N. 2833. We reject this result.
(1) which states conspicuously (A) the name
and place of business of the manufacturer,
packer, distributor or seller; (B) the common
or usual name or the chemical name (if there
be no common or usual name) of the hazardous
substance or of each component which
contributes substantially to its hazard,
unless the Commission by regulation permits or
requires the use of a recognized generic name;
(C) the signal word "DANGER" on substances
which are extremely flammable, corrosive, or
highly toxic; (D) the signal word "WARNING" or
"CAUTION" on all other hazardous substances;
(E) an affirmative statement of the principal
hazard or hazards, such as "Flammable",
"Combustible", "Vapor Harmful", "Causes
Burns", "Absorbed Through Skin", or similar
wording descriptive of the hazard; (F)
precautionary measures describing the action
to be followed or avoided, except when
modified by regulation of the Commission
pursuant to section 1262 of this title ....
Unlike the situation in Busch v. Graphic Color Corp., 169 Ill.
2d at
342, 662 N.E.
2d at 406, there is no specific label exemplar
provided by the federal Commission for products with less than 4"
methyl alcohol, such as the "stain-killer" in this case.
We conclude as a matter of law that Zinsser's "stain-killer"
generally and adequately complies with § 1261(p) because the label
"states conspicuously" all the necessary statutory elements for
this product and this use:
1. The name and place of business of the
manufacturer: "William Zinsser & Co., Inc., 39
Belmont Drive, Somerset, N.J. 08875."
2. The common chemical name of the hazardous
substance .... "alcohol."
3. A DANGER label is not applicable here as
the product is not "highly toxic," as in 16
C.F.R. § 1500.14 regulated products.
4. The signal words CAUTION and WARNING are
present.
5. An affirmative statement of the principal
hazard or hazards and precautionary measures
describing the action to be followed or
avoided is present.
WARNING: FLAMMABLE (SEE OTHER
CAUTIONS ON BACK PANEL)
CAUTION: FLAMMABLE. Contains
alcohol. Keep away from heat,
sparks, and open flame. Use with
adequate ventilation. Avoid
prolonged breathing of vapor or
contact with skin. Do not take
internally. Close can after using.
We also conclude that the statements required by § 1261(p)(1)
comply with the standard of § 1261(p)(2) because the graphics "are
located prominently and are in the English language in conspicuous
and legible type in contrast by topography, layout or color with
other printed matter on the label." The lettering on the Zinsser
can is red or black type on a white background.
Plaintiff's expert claims that the Zinsser can of "stain-killer" should have had a more detailed, elaborate, or amplified
warning than required by § 1261(p). Plaintiff's expert, Leslie Z.
Lefkovic's report of September 28, 1993 stated:
The B-I-N label states "use with adequate
ventilation, avoid prolonged breathing of
vapor or contact with skin." This is a
watered down, vague and inadequate warning for
a person using this product. This label does
not explain in adequate terms what adequate
ventilation is. The manufacturer is in the
best position to indicate the correct
ventilation. It is reasonably foreseeable
that the user will apply the product in the
manner described by Ms. Gurrieri. As a result
of her reasonable use of the product as
foreseeable by the manufacturer she was
probably exposed to hazardous vapors at
concentrations much higher than those
permitted by OSHA.
There is no indication that she misused
the product or used it in a manner
inconsistent with the directives as reasonably
expected by the manufacturer for a consumer or
user of the product.
The label should emphasize much stronger
the need of open windows and doors and of use
of other means to ensure entry of fresh air
like a fan with explosion proof motor and or
use of NIOSH approved gas masks.
The deposition transcript indicates that
there was dripping in her eye. This should
have been anticipated by the manufacturer.
The B-I-N label states "Avoid contact
with skin"
Again the label should warn the user of
the hazard before any contact with skin and
advise to use goggles and gloves. This was
not done on this product.
The third part of the health effect warning is
ingestion, which is self-explanatory.
In an effect [sic] within reasonable
probability, the product was labeled
inadequately to warn the user of the proper
precautions when using this product which
contains hazardous substances.
Ultimately, this case as presented to us boils down to a
quarrel about the efficacy of the warning label. We conclude that
the label used by defendant Zinsser met the standard set by
15 U.S.C.A.
§1261(p) of the FHSA as a matter of law. Plaintiff's
expert may not impose a more stringent standard than federal law;
state product liability law may not require a more vigorous or
detailed warning standard.
Affirmed.
Footnote: 1The FHSA defines "hazardous substance" as:
(f) The term "hazardous substance" means:
(1)(A) Any substance or mixture
of substances which (i) is toxic,
(ii) is corrosive, (iii) is an
irritant, (iv) is a strong
sensitizer, (v) is flammable or
combustible, or (vi) generates
pressure through decomposition,
heat, or other means, if such
substances or mixture of substances
may cause substantial personal
injury or substantial illness during
or as a proximate result of any
customary or reasonably foreseeable
handling or use, including
reasonably foreseeable ingestion by
children.
[
15 U.S.C.A.
§1261(f)(1)(A).]
The FHSA defines "toxic" as:
(g) The term "toxic" shall apply to any
substance (other than a radioactive substance)
which has the capacity to produce personal
injury or illness to man through ingestion,
inhalation, or absorption through any body
surface.
[
15 U.S.C.A.
§1261(g).]
Footnote: 2 The Supreme Court of New Jersey affirmed our decision to
dismiss plaintiff's failure-to-warn claims but modified our
judgment by remanding for retrial on the issues of plaintiff's
comparative fault and defendants' liability.